|
|
Article: Focalin(TM) LA Pivotal Clinical Trial Initiated in Adults With ADD/ADHD.
- Article from:
- PR Newswire
- Article date:
- July 2, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Celgene Corporation announced today that a pivotal clinical trial of Focalin(TM) LA (dexmethylphenidate hydrochloride extended-release capsules) in adults with attention deficit disorder / attention deficit hyperactivity disorder (ADD/ADHD) has been initiated. Novartis Pharmaceuticals Corporation has marketing rights to Focalin LA in the United States and will conduct the multi-center, controlled pivotal trial to evaluate the safety and efficacy of Focalin LA administered once daily in adult patients with ADD/ADHD.
Attention deficit disorder/attention deficit hyperactivity disorder is a recognized medical disorder characterized by persistent symptoms of ...